Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc. (AVTX), sold 108,234 shares at $16.00 ($2.2M) on 2026-05-05, disclosed to the SEC on 2026-05-07.
Scheduled sale ($2.2M) by Chief Medical Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.00 | 1,679 | $27K | 1.2% |
| 2 | $18.03 | 27,538 | $496K | 22.3% |
| 3 | $19.65 | 5,000 | $98K | 4.4% |
| 4 | $21.20 | 44,944 | $953K | 42.7% |
| 5 | $22.41 | 19,015 | $426K | 19.1% |
| 6 | $22.88 | 10,058 |
| $230K |
| 10.3% |
| Total | $20.61 avg | 108,234 | $2.2M | 100% |
| Filing → |
| AVTX | SELL | 2026-08-12 | $14K | — | Filing → |
| AVTX | SELL | 2026-07-29 | $20K | — | Filing → |
| AVTX | SELL | 2026-07-02 | $93K | — | Filing → |